The FDA has accepted Stealth BioTherapeutics’ resubmission of its new drug application for elamipretide, a treatment for Barth syndrome.
The agency set an earlier review target date of Sept. 26, ahead of the Feb. 15 deadline, according to an Aug. 21 news release from the drugmaker.
Approximately 150 people in the U.S. have Barth syndrome, a rare disorder that can cause heart failure. This move comes after decades of development and the FDA rejecting the drug in May with no explanation.
The company had resubmitted the application Aug. 15 after receiving a complete response in May, and the submission seeks accelerated approval based on data showing more than 45% improvement in muscle strength in a phase 2 trial. A postmarketing trial is also planned to confirm clinical benefits, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.